NEWS
Valrubicin
  • Approved Drug Name
    Valrubicin
  • CAS NO.
    56124-62-0
  • Quality Standard
    USP
  • Packaging
    10G/Bag, 20G/Bag
  • Storage Condition
    Shading,Sealing,Store at room temperature
  • Certification
    Ongoing registration

Valrubicin(casno.56124-62-0) (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin(casno.56124-62-0) is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues. Valstar was relaunched on September 3, 2009.
Valrubicin(casno.56124-62-0) (N-trifluoroacetyladriamycin-14-valerate), a semisynthetic analog of the anthra-cycline doxorubicin, is a cytotoxic agent with the chemical name, (2S-cis)-2-[1,2,3,4, 6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxyl]-2-naphthacenyl]-2-oxoethyl pentanoate. Valrubicin(casno.56124-62-0) is an orange or orange-red powder that is highly lipophilic, soluble in methylene chloride, ethanol, methanol and acetone, and relatively insoluble in water. Its chemical formula is C34H36F3NO13 and its molecular weight is 723.65.
What is Valrubicin(casno.56124-62-0)?
Valrubicin(casno.56124-62-0) is a cancer (antineoplastic) medication. Valrubicin(casno.56124-62-0) interferes with the growth of cancer cells and slows their growth and spread in the body.
Valrubicin(casno.56124-62-0) is used to treat bladder cancer.
Valrubicin(casno.56124-62-0) may also be used for purposes other than those listed in this medication guide.
What are the possible side effects of Valrubicin(casno.56124-62-0)?
If you experience an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives) to Valrubicin(casno.56124-62-0), seek emergency medical attention.
Other, less serious side effects may be more likely to occur. Continue taking Valrubicin(casno.56124-62-0) and talk to your doctor if you experience:
Bladder irritation (increased frequency of urination, painful urination, a very strong feeling of needing to urinate, blood in the urine);
Urinary incontinence;
Urinary tract infection;
Red colored urine for 24 hours following a dose; or nausea.
What is the most important information I should know about Valrubicin(casno.56124-62-0)?
Valrubicin(casno.56124-62-0) should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.
Serious side effects have been reported with the use of Valrubicin(casno.56124-62-0) including: allergic reactions (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); severe heart damage with prolonged use; decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; fever or chills; or signs of infection); severe nausea, vomiting, diarrhea, and loss of appetite; and others. Talk to your doctor about the possible side effects from treatment with Valrubicin(casno.56124-62-0).
Who should not use Valrubicin(casno.56124-62-0)?
Do not use Valrubicin(casno.56124-62-0) without first talking to your doctor if you have a urinary tract infection;
a perforated or otherwise damaged bladder;
kidney disease; or irritable bladder disorder.
The use of Valrubicin(casno.56124-62-0) may be dangerous if you have any of the conditions listed above.
Valrubicin(casno.56124-62-0) is in the FDA pregnancy category C. Systemic exposure to Valrubicin(casno.56124-62-0) may result in harm to an unborn baby. Do not use Valrubicin(casno.56124-62-0) without first talking to your doctor if you are pregnant. Men and women being treated with Valrubicin(casno.56124-62-0) should discuss with their doctor the appropriate use of birth control during treatment with Valrubicin(casno.56124-62-0) if necessary. Because of the potential for serious side effects in a nursing infant, breast-feeding should be avoided during treatment with Valrubicin(casno.56124-62-0). The safety and effectiveness of Valrubicin(casno.56124-62-0) in children has not been established.
How should I use Valrubicin(casno.56124-62-0)?
Valrubicin(casno.56124-62-0) should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.
Your doctor will determine the correct amount and frequency of treatment with Valrubicin(casno.56124-62-0) depending upon the type of cancer being treated and other factors. Valrubicin(casno.56124-62-0) has caused a complete response in only about 1 in 5 patients and delaying surgery could lead to wide-spread bladder cancer, which is lethal. Talk to your doctor if you have any questions or concerns regarding the treatment schedule.
Your doctor will probably want you to have regularly scheduled blood tests and other medical evaluations during treatment with Valrubicin(casno.56124-62-0) to monitor progress and side effects.
Skin accidentally exposed to Valrubicin(casno.56124-62-0) should be rinsed thoroughly with soap and warm water.
Your healthcare provider will store Valrubicin(casno.56124-62-0) as directed by the manufacturer. If you are storing Valrubicin(casno.56124-62-0) at home, follow the directions provided by your healthcare provider.
keywords
Valrubicin Quality
Valrubicin Manufacturers
Valrubicin Suppliers
Valrubicin FDA
Valrubicin USP.EP
Valrubicin GMP
Valrubicin price
Valrubicin samples
What happens if I miss a dose?
Contact your doctor if you miss a dose of Valrubicin(casno.56124-62-0).
What happens if I overdose?
If for any reason an overdose of Valrubicin(casno.56124-62-0) is suspected, seek emergency medical attention or contact your healthcare provider immediately.
Symptoms of a Valrubicin(casno.56124-62-0) overdose tend to be similar to side effects caused by the medication, although often more severe.
What should I avoid while using Valrubicin(casno.56124-62-0)?
Valrubicin(casno.56124-62-0) can lower the activity of your immune system making you susceptible to infections. Avoid contact with people who have colds, the flu, or other contagious illnesses and do not receive vaccines that contain live strains of a virus (e.g., live oral polio vaccine) during treatment with Valrubicin(casno.56124-62-0). In addition, avoid contact with individuals who have recently been vaccinated with a live vaccine. There is a chance that the virus can be passed on to you.
Skin accidentally exposed to Valrubicin(casno.56124-62-0) should be rinsed thoroughly with soap and warm water.
What other drugs will affect Valrubicin(casno.56124-62-0)?
Do not receive "live" vaccines during treatment with Valrubicin(casno.56124-62-0). Administration of a live vaccine may be dangerous during treatment with Valrubicin(casno.56124-62-0).
Other drugs may interact with Valrubicin(casno.56124-62-0). Talk to your doctor and pharmacist before taking any other prescription or over-the-counter medicines, including herbal products, during treatment with Valrubicin(casno.56124-62-0).